Source link : https://www.newshealth.biz/health-news/europe-approves-paroxysmal-nocturnal-hemoglobinuria-drug/
The first-in-class complement factor D inhibitor danicopan (Voydeya) has been approved by the European Commission as an add-on agent for certain patients with the rare disease paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare, chronic, progressive, multisystemic disease caused by an acquired genetic mutation of the X-linked gene PIGA. The mutation results in the expansion […]
Author : News Health
Publish date : 2024-04-23 15:01:44
Copyright for syndicated content belongs to the linked Source.